Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
In this 52-week trial of 1,698 people with type 2 diabetes whose blood sugar wasn't adequately controlled on Metformin, orforglipron outperformed oral semaglutide on every primary and secondary endpoint, including A1C reduction and weight loss, with improvements visible as early as four weeks
Its all connected
Strinic D, Belosic Halle Z, Luetic K, Nedic A, Petrovic I, Sucic M, Zivanovic Posilovic G, Balenovic D, Strbe S, Udovicic M, Drmic D, Stupnisek M, Lovric Bencic M, Seiwerth S, Sikiric P
Check out our white paper, Analysis of Glucagon-Like Peptide-1 Agonist Trends Within An Integrated Health System Specialty Pharmacy, on how an integrated pharmacy model improves adherence and reduces out-of-pocket costs for GLP1 drugs.
US$ 25.07
US$ 25.69
US$ 25.31
